Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/209233
Title: CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood
Author: Egri, Natalia
Olivé, Victoria
Hernández Rodríguez, José
Castro, Pedro
Guzman, Catherine de
Heredia, Libertad
Cstellet Segura, Ana
Fernández, M. Dolores
Moner, Noemí de
Torradeflot, María
Ballús, Judit
Martínez, Robert
Vázquez, Mario
Vidal Costa, Marta
Dobaño, Carlota
Mazza, Massimiliano
Mazzotti, Lucia
Pascal, Mariona
Juan, Manel
González Navarro, Europa Azucena
Calderón, Hugo
Keywords: COVID-19
Diagnòstic
COVID-19
Diagnosis
Issue Date: 6-Jul-2023
Publisher: Frontiers
Abstract: Cellular and humoral immune responses are essential for COVID-19 recovery and protection against SARS-CoV-2 reinfection. To date, the evaluation of SARS-CoV-2 immune protection has mainly focused on antibody detection, generally disregarding the cellular response, or placing it in a secondary position. This phenomenon may be explained by the complex nature of the assays needed to analyze cellular immunity compared with the technically simple and automated detection of antibodies. Nevertheless, a large body of evidence supports the relevance of the T cell's role in protection against SARS-CoV-2, especially in vulnerable individuals with a weakened immune system (such as the population over 65 and patients with immunodeficiencies). Here we propose to use CoVITEST (Covid19 anti-Viral Immunity based on T cells for Evaluation in a Simple Test), a fast, affordable and accessible in-house assay that, together with a diagnostic matrix, allows us to determine those patients who might be protected with SARS-CoV-2-reactive T cells. The method was established using healthy SARS-CoV-2-naïve donors pre- and post-vaccination (n=30), and further validated with convalescent COVID-19 donors (n=51) in a side-by-side comparison with the gold standard IFN-? ELISpot. We demonstrated that our CoVITEST presented reliable and comparable results to those obtained with the ELISpot technique in a considerably shorter time (less than 8 hours). In conclusion, we present a simple but reliable assay to determine cellular immunity against SARS-CoV-2 that can be used routinely during this pandemic to monitor the immune status in vulnerable patients and thereby adjust their therapeutic approaches. This method might indeed help to optimize and improve decision-making protocols for re-vaccination against SARS-CoV-2, at least for some population subsets.Copyright © 2022 Egri, Olivé, Hernández-Rodríguez, Castro, De Guzman, Heredia, Segura, Fernandez, de Moner, Torradeflot, Ballús, Martinez, Vazquez, Costa, Dobaño, Mazza, Mazzotti, Pascal, Juan, González-Navarro and Calderón.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.848586
It is part of: Frontiers In Immunology, 2022, vol. 13
URI: http://hdl.handle.net/2445/209233
Related resource: https://doi.org/10.3389/fimmu.2022.848586
ISSN: 1664-3224
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
CoVITEST A Fast and Reliable Method to Monitor Anti-SARS-CoV-2_FrontiersInImmunology.pdf2.19 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons